Physician profile
Joseph Losurdo
NPI 1437261450
$746.20
in general payments reported to CMS, 2019-2025
14 companies · $27.04 in 2025
The $27.04 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.06 · 2020: $35.63 · 2021: $106 · 2022: $219 · 2023: $52.39 · 2024: $244 · 2025: $27.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $315.95 | 2021-2024 | Stelara |
| Celgene Corporation | $196.62 | 2023-2024 | Zeposia |
| Abbvie INC. | $38.90 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $37.15 | 2023-2024 | Linzess |
| Ardelyx, INC. | $27.04 | 2025 | Ibsrela |
| Allergan, INC. | $24.57 | 2019 | |
| Gilead Sciences, INC. | $21.68 | 2024 | |
| Pfizer INC. | $20.94 | 2019 | |
| Vivus LLC | $15.04 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.68 | 2021 | |
| Shionogi INC | $12.32 | 2020 | |
| Merck Sharp & Dohme LLC | $12.29 | 2020 | |
| Braintree Laboratories, INC. | $11.02 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$73,009.02 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Losurdo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.